Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma.
Fourteen patients with advanced renal cell carcinoma were treated on a phase II trial with liposomal encapsulated doxorubicin (Lipodox, LED). None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity and no cardiac toxicity was evident. Seventy-nine percent (11 of 14) of patients experienced grade III or IV neutropenia. In summary, LED did not show antitumor activity in the treatment of advanced renal cell carcinoma.
Law
T M
TM
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Mencel
P
P
Motzer
R J
RJ
D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004317:Doxorubicin / Q000008:administration & dosage*; D004337:Drug Carriers; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008081:Liposomes; D008297:Male; D008875:Middle Aged
D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin